Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration
Authors
Keywords
-
Journal
Nature Nanotechnology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-28
DOI
10.1038/s41565-022-01225-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
- (2022) A. Filippone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Specific Endothelial Cells Govern Nanoparticle Entry into Solid Tumors
- (2021) Benjamin R. Kingston et al. ACS Nano
- Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy
- (2021) Xiaoqi Sun et al. Nature Nanotechnology
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
- (2020) Chunyong Ding et al. Acta Pharmaceutica Sinica B
- Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
- (2020) Ilgen Mender et al. CANCER CELL
- Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion
- (2020) Jianjun Wu et al. IMMUNITY
- Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
- (2020) Henrique Lemos et al. Journal for ImmunoTherapy of Cancer
- Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
- (2020) Yihan Yao et al. Frontiers in Molecular Biosciences
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
- (2019) Xiaopin Duan et al. Nature Communications
- Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages
- (2019) Marco Orecchioni et al. Frontiers in Immunology
- STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- (2019) Hannah Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
- (2019) Daehwan Kim et al. NATURE BIOTECHNOLOGY
- cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
- (2019) Zining Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- STING promotes homeostasis via regulation of cell proliferation and chromosomal stability
- (2018) Diana Rose E. Ranoa et al. CANCER RESEARCH
- The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses
- (2017) Liangshun You et al. Journal of Hematology & Oncology
- Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages?
- (2017) Takayuki Ohkuri et al. Human Vaccines & Immunotherapeutics
- Liposomal Formulations in Clinical Use: An Updated Review
- (2017) Upendra Bulbake et al. Pharmaceutics
- RNA-Seq differential expression analysis: An extended review and a software tool
- (2017) Juliana Costa-Silva et al. PLoS One
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
- (2016) Qi Chen et al. NATURE IMMUNOLOGY
- Current and future strategies for treatment of glioma
- (2016) Nancy Ann Oberheim Bush et al. NEUROSURGICAL REVIEW
- Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
- (2016) Wenxin Zheng et al. Oncotarget
- Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis
- (2016) Tianli Xia et al. Cell Reports
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
- (2014) Edward A. Sykes et al. ACS Nano
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
- (2014) Pu Gao et al. Cell Reports
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
- (2012) J. Wu et al. SCIENCE
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
- (2011) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
- (2010) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
- (2009) Hiroki Ishikawa et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search